WCN25-3676 RESULTS FROM THE REGENCY TRIAL ASSESSING EFFICACY AND SAFETY OF OBINUTUZUMAB IN ACTIVE LUPUS NEPHRITIS

WCN25-3676 RESULTS FROM THE REGENCY TRIAL ASSESSING EFFICACY AND SAFETY OF OBINUTUZUMAB IN ACTIVE LUPUS NEPHRITIS

Saved in:

Bibliographic Details
Main Authors:	Brad Rovin, Richard Furie, Jay Garg, Mittermanyer Santiago, Gustavo Aroca-Martinez, Adolfina Elizabeth Zuta Santillan, Harini Raghu, Imran Hassan, Bongin Yoo, Elsa Martins, Himanshi Sehgal, Theodore Omachi, Thomas Schindler, William Pendergraft, Ana Malvar
Format:	Article
Language:	English
Published:	Elsevier 2025-02-01
Series:	Kidney International Reports
Online Access:	http://www.sciencedirect.com/science/article/pii/S2468024924033825
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Extremely Long-Lasting B-cell Depletion and BAFFling Effects Following Obinutuzumab-Based Regimen in Lupus Nephritis
by: Dario Roccatello, et al.
Published: (2024-10-01)

The Evolution of Crescents in Lupus Nephritis
by: Ana Malvar, et al.
Published: (2025-05-01)

The Occurrence of Richter’s Syndrome during Treatment with Obinutuzumab and Chlorambucil
by: Teng Fong Ng, et al.
Published: (2020-01-01)

Organising Pneumonia in a Patient Following Obinutuzumab for Follicular Lymphoma
by: Viral Nanda, et al.
Published: (2025-06-01)

Obinutuzumab for Relapsing Myeloperoxidase-Antineutrophil Cytoplasmic Autoantibody–Associated Glomerulonephritis
by: Michael Cammarata, et al.
Published: (2025-06-01)

Obinutuzumab in Rituximab-Resistant Podocytopathies: A Single-Center Experience
by: Andrea Angeletti, et al.
Published: (2025-08-01)

Obinutuzumab as Initial or Second-Line Therapy in Patients With Primary Membranous Nephropathy
by: Xiaole Su, et al.
Published: (2024-08-01)

Obinutuzumab in Rituximab-Intolerant Antineutrophil Cytoplasmic Antibody–Associated Vasculitis Patients
by: Jolijn R. van Leeuwen, et al.
Published: (2025-04-01)

Obinutuzumab-induced acute thrombocytopenia: a case report and literature review
by: Xuelin Dou, et al.
Published: (2024-12-01)

Obinutuzumab en glomerulonefritis focal y segmentaria resistente al tratamiento
by: Byron Chiliquinga Morales, et al.
Published: (2025-04-01)

Treatment with obinutuzumab plus venetoclax reshapes the TRB repertoire of CLL patients
by: Paul J. Hengeveld, et al.
Published: (2025-01-01)

Outcome of participants with nephrotic syndrome in combined clinical trials of lupus nephritis
by: Brad Rovin, et al.
Published: (2019-12-01)

Obinutuzumab-induced severe acute thrombocytopenia: a case report and literature review
by: Kun Kou, et al.
Published: (2025-08-01)

Efficacy and safety of obinutuzumab in primary membranous nephropathy: a real-world retrospective study
by: Xi Cheng, et al.
Published: (2025-08-01)

Assessment of the feed additives consisting of Lactiplantibacillus plantarum DSM 3676, Lactiplantibacillus plantarum DSM 3677 and Lentilactobacillus buchneri DSM 13573 for all animal species for the renewal of their authorisations (ADDCON GmbH)
by: EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP), et al.
Published: (2023-07-01)

Innovative therapeutic strategy for B-cell malignancies that combines obinutuzumab and cytokine-induced killer cells
by: Elisa Cappuzzello, et al.
Published: (2021-07-01)

Phase II study of venetoclax added to bendamustine and obinutuzumab in patients with high-risk follicular lymphoma as front-line therapy: PrE0403
by: Craig A. Portell, et al.
Published: (2025-05-01)

Obinutuzumab and Ofatumumab are More Effective Than Rituximab in the Treatment of Membranous Nephropathy Patients With Anti-Rituximab Antibodies
by: Maxime Teisseyre, et al.
Published: (2025-03-01)

Obinutuzumab combined with bendamustine for the treatment of hairy cell leukemia variant: a case report and literature review
by: Junjun Bai, et al.
Published: (2025-08-01)

Debulking Therapy with Obinutuzumab Is Helpful and Safe in Chronic Lymphocytic Leukemia with Extreme Hyperleukocytosis: A Case Report
by: Dario Leotta, et al.
Published: (2025-03-01)

Obinutuzumab for treatment of membranous nephropathy in patients positive and negative for the phospholipase A2 receptor antibody: case reports
by: Jinmeng Wang, et al.
Published: (2025-04-01)

WCN24-1086 THE EFFICIENCY AND SAFETY OF OBINUTUZUMAB IN THE TREATMENT OF MEMBRANOUS NEPHROPATHY-A RETROSPECTIVE STUDY FROM CHINA
by: Chen Duqun, et al.
Published: (2024-04-01)

Obinutuzumab induction and maintenance in patients with Waldenström macroglobulinaemia: an open-label, single-arm phase 2 studyResearch in context
by: Tomasz Wróbel, et al.
Published: (2025-08-01)

Obinutuzumab is Effective as an Initial Treatment for PLA2R-Associated Primary Membranous Nephropathy: A Retrospective, Single-Center Trial
by: Li XQ, et al.
Published: (2025-07-01)

Early caplacizumab and obinutuzumab enable successful treatment of relapsing thrombotic thrombocytopenic purpura without therapeutic plasma exchange: a case report
by: Judith Schimpf, et al.
Published: (2025-04-01)

Rethinking the feasibility and safety of venetoclax-obinutuzumab in chronic lymphocytic leukemia: non-traditional factors may play a role in clinical practice
by: Anna Maria Frustaci, et al.
Published: (2025-06-01)

WCN24-2425 THE CHRONICITY INDEX FOR LN BIOPSIES SHOULD BE MODIFIED TO EXCLUDE FIBROUS CRESCENTS?
by: Valeria Alberton, et al.
Published: (2024-04-01)

Disease-Modifying Therapies in Lupus Nephritis: A Narrative Review Evaluating Currently Used Pharmacologic Agents
by: Anca D. Askanase, et al.
Published: (2025-04-01)

Chemotherapy-free combination of ibrutinib and obinutuzumab for untreated advanced follicular lymphoma: results of a phase II study from the German Lymphoma Alliance
by: Christian Schmidt, et al.
Published: (2025-06-01)

Study protocol for a randomised, phase II, double-blind, experimental medicine study of obinutuzumab versus rituximab in ANCA-associated vasculitis: ObiVas
by: Simon Bond, et al.
Published: (2024-07-01)

Effectiveness and Safety of Polatuzumab Vedotin Plus an Anti‐CD20 Monoclonal Antibody (Rituximab or Obinutuzumab) and Zanubrutinib in Relapsed/Refractory Diffuse Large B‐Cell Lymphoma
by: Yian Zhang, et al.
Published: (2025-08-01)

Obinutuzumab in Combination with Alternative Chlorambucil Schedules in Front-Line Treatment of Chronic Lymphocytic Leukemia: A Study by KroHem, the Croatian Cooperative Group for Hematologic Diseases
by: Igor Aurer, et al.
Published: (2024-12-01)

Efficacy, pharmacokinetics and safety of iscalimab (CFZ533) in patients with proliferative lupus nephritis: a randomised, double-blind, placebo-controlled, phase II study
by: Renaud Felten, et al.
Published: (2025-08-01)

Prospects for the use of belimumab in lupus nephritis
by: N. L. Kozlovskaya, et al.
Published: (2021-08-01)

Evaluation of Treatment Response in Lupus Nephritis
by: Anca BOBIRCA, et al.
Published: (2021-12-01)

Recent advances in the treatment of lupus nephritis
by: Wan-xing Li, et al.
Published: (2022-08-01)

USE OF RITUXIMAB IN PATIENTS WITH LUPUS NEPHRITIS
by: Anna Vasilyevna Torgashina, et al.
Published: (2010-08-01)

Clinical application of belimumab in lupus nephritis
by: Zhou Han, et al.
Published: (2022-10-01)

Sildenafil Induced Acute Interstitial Nephritis
by: Ryan Burkhart, et al.
Published: (2015-01-01)

Tubulointerstitial nephritis in cases of lupus nephritis: An experience from a tertiary care referral center of Eastern India
by: Keya Basu, et al.
Published: (2022-09-01)